Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Therapy applied directly inside the eye best for treating uveitic macular edema

Therapy applied directly inside the eye best for treating uveitic macular edema

Credit: CC0 Public Domain

Delivery of corticosteroids directly into the eye is more effective than injections adjacent to the eye, according to results from a comparative clinical trial of macular edema in patients with noninfectious uveitis. The study was funded by the National Eye Institute (NEI), part of the National Institutes of Health. The results were published online today in the journal Ophthalmology.

Uveitis—a collection of inflammatory conditions that affect internal eye tissues—is a leading cause of blindness in the United States and can be chronic. About 40 percent of people with uveitis affecting the middle or back of the eye develop macular edema, a build-up of fluid in the macula, which is the region of the retina responsible for central vision. Systemic corticosteroids, which help reduce inflammation, typically are used to treat chronic uveitis. But additional treatment with regional corticosteroid injections is often needed to treat macular edema.

“Macular edema is a significant structural ocular complication of uveitis, which causes loss of visual acuity,” said Jennifer E. Thorne, M.D., Ph.D., professor of ophthalmology and epidemiology at the Wilmer Eye Institute, Johns Hopkins Medical Institutions and the lead author of the study, “so it’s important to be able to treat this condition effectively in order to restore central acuity and prevent retinal damage.”

The researchers compared three commonly used corticosteroid treatments for macular edema in patients with uveitis: periocular (adjacent to the eye) injection of triamcinolone acetonide (Kenalog); intravitreal (inside the eye) injection of triamcinolone acetonide (Triesence); and intravitreal injection of a dexamethasone implant (Ozurdex), which slowly releases the drug inside the eye over several months. The clinical trial included 192 people with uveitis, ranging in age from 18 to 87 years old, who were randomly assigned to one of the three treatments. Participants were evaluated at several timepoints for macular thickness; macular edema; visual acuity; and high intraocular pressure (IOP), a common side-effect of corticosteroid therapy.

At the eight-week primary outcome visit, all treatment groups had improvements in macular edema when compared to baseline. However, the two intravitreal groups had larger reductions in macular edema when compared to the results in the periocular treatment group. Reduction from baseline was 46 percent, 39 percent, and 23 percent for the dexamethasone implant, intravitreal triamcinolone, and periocular triamcinolone treatment groups, respectively. While all the treatments led to improvement in vision, those receiving intravitreal triamcinolone or dexamethasone implant showed an average of nine standard letters improvement (about two lines on an eye chart), versus four standard letters for those receiving the periocular injection treatment.

“Although all three treatments reduced macular edema and increased visual acuity, the data show superior efficacy for intravitreal triamcinolone and the intravitreal dexamethasone implant, which suggests that the approach to treatment for uveitic macular edema should be through the intravitreal route,” said Douglas A. Jabs, M.D., M.B.A., professor of ophthalmology and medicine at the Icahn School of Medicine at Mount Sinai, chair of the Multicenter Uveitis Steroid Treatment Trial Research Group, which conducted the research.

Direct delivery of corticosteroids to the eye can lead to high IOP and glaucoma—a disease that causes optic nerve damage. While more participants who received intravitreal delivery of corticosteroids showed a rise in IOP, compared to patients receiving periocular injections, this higher pressure was largely controlled with drugs.

“This trial included people already receiving IOP-lowering medications and those with previous history of glaucoma or glaucoma surgery,” said Thorne. “It was reassuring to see that IOP elevations were moderate and controllable with medication through the six-month period of the study even in patients with a previous history of IOP elevations and glaucoma.”

While each of these three treatments have been studied previously and have been shown to be effective in treating macular edema complications of uveitis, this is the first head-to-head comparison.

“The POINT Trial, funded by the NEI, provides evidence to guide the clinicians in the utilization of the most commonly used regional corticosteroid injections for uveitic macular edema,” said Sangeeta Bhargava, Ph.D., program director for clinical research at NEI.

“These data will improve the management of patients with uveitis, and demonstrate the importance of NIH-funded comparative effectiveness trials,” said Jabs.


Explore further:
Aflibercept rescues vision after laser for diabetic macular edema

More information:
Thorne JE, Sugar EA, et al. “Periocular triamcinolone versus intravitreal triamcinolone versus intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular versus INTravitreal corticosteroids for uveitic macular edema (POINT) Trial.” September 27, 2018; Ophthalmology.

Journal reference:
Ophthalmology

Provided by:
National Eye Institute

Tagged with:

About author

Related Articles